预约演示
更新于：2026-02-27
Famotidine
法莫替丁
更新于：2026-02-27
概要
基本信息
简介法莫替丁是一种药物，可以帮助患有胃炎和消化性溃疡等胃病的人。它属于一组称为 H2 受体拮抗剂的药物，其作用是阻止胃产生过多的酸。当胃酸过多时，人们会感到很痛，如胃灼热或消化不良。法莫替丁真的很擅长减少胃酸，让人感觉更好。它有不同的形式，如药片和注射剂，因此人们可以选择最适合自己的方式。 Bausch Health Americas 于 1986 年生产了法莫替丁，此后被很多人使用。人们应该确保按照医生的指示服用法莫替丁，以确保其正常工作并避免任何副作用。 |
药物类型 小分子化药 |
别名 (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide、3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide、3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine + [40] |
作用方式 拮抗剂 |
作用机制 H2 receptor拮抗剂(组胺H2受体拮抗剂) |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H15N7O2S3 |
InChIKeyXUFQPHANEAPEMJ-UHFFFAOYSA-N |
CAS号76824-35-6 |
关联
152
项与 法莫替丁 相关的临床试验NCT06507904
A Phase 1, Randomized, Crossover Design Study to Assess Palatability of Osivelotor (PF-07940367) Pediatric Formulations With Dosing Vehicle (Part 1) and Randomized, Single-Dose, Parallel Design Study to Estimate Relative Bioavailability of Osivelotor Pediatric Formulation With Dosing Vehicle and With Water Compared to Clinical Tablet Formulation, and Effect of Food and/or Acid-Reducing Agent On Bioavailability In Healthy Adult Participants (Part 2)
NCT07101445
Prevent Allergic Reactions to Aphexda With Dexamethasone (PARADE)
NCT07171619
A Phase 1, Single-Sequence, 3 Period Crossover, Open-Label Study to Determine the Effect of Rabeprazole or H2 Blocker Famotidine on the Pharmacokinetics of Nirogacestat in Healthy Adult Male Participants
100 项与 法莫替丁 相关的临床结果
登录后查看更多信息
100 项与 法莫替丁 相关的转化医学
登录后查看更多信息
100 项与 法莫替丁 相关的专利（医药）
登录后查看更多信息
3,318
项与 法莫替丁 相关的文献（医药）2026-05-01EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Personalized oral drug delivery via FDM 3D printing: Polyvinyl alcohol capsules with tunable release profiles supported by in silico modeling
Article
作者: Al-Tabakha, Moawia M ; Chan, Siok Yee ; Yasin, Haya Khader Ahmad
Three-dimensional (3D) printing by Fused Deposition Modeling (FDM) offers a flexible platform for fabricating personalized medicines with tunable release profiles. However, developing printable filaments with suitable mechanical properties and controlled drug release remains challenging. Ketoprofen was formulated into FDM-printed polyvinyl alcohol (PVA) capsule shells which were subsequently filled with ketoprofen powder and locked to form complete 3D‑printed capsules, spanning immediate-, sustained-, and delayed-release designs; a dual-compartment polypill with famotidine was also produced. Capsule shell geometry and internal density were systematically varied to modulate drug release, and performance was evaluated using pharmacopeial quality tests, dissolution studies, micro-computed tomography, and in silico pharmacokinetic simulation. Capsule geometry and polymer choice modulated release: low shells/infill density accelerated immediate-release (IR) whilst higher shells/infill density prolonged sustained-release (SR). Selected IR and SR capsules achieved a similarity factor f2 ≥ 50 vs references. Micro-CT confirmed design-porosity differences; solid-state data supportedthe formation of largely amorphous solid drug-polymer dispersions in Kollicoat IR formulations and solvent evaporation products. Simulations predicted distinct IR vs SR plasma profiles. These findings illustrate that FDM printing can modulate oral drug release through geometry and, together with in silico tools, provide a framework for designing customized capsules.
2026-04-01DEN open
Olmesartan‐induced gastritis with no lower gastrointestinal symptoms: A case report
Article
作者: Miki Kamiyama ; Masahiro Ochi ; Satoshi Kosaka
Abstract:
A 74‐year‐old man with decreased appetite, weight, and heartburn was referred to our hospital. His medications included olmesartan. Esophagogastroduodenoscopy (EGD) revealed antral‐dominant erosive gastritis and nodular mucosa. A gastric biopsy revealed inflammatory cell infiltration. The serum anti‐Helicobacter pylori immunoglobulin G antibody test result was negative. Famotidine was ineffective in relieving his symptoms, and esomeprazole failed to prevent overt gastric bleeding, which required endoscopic hemostasis. The working diagnosis was drug‐induced gastritis, particularly olmesartan‐induced gastritis. His appetite loss started to improve within a week of olmesartan withdrawal. The erosions healed on EGD 2 months later. Over the next 10 months, he remained in his usual state until olmesartan was inadvertently administered. Subsequent EGD revealed a mild gastritis relapse. We diagnosed olmesartan‐induced gastritis and discontinued olmesartan treatment. Mucosal healing was confirmed by EGD 1 year later. Olmesartan is known to cause angiotensin II receptor blocker‐induced enteropathy. Although angiotensin II receptor blocker‐induced enteropathy affects the stomach, angiotensin II receptor blocker‐induced gastritis without lower gastrointestinal symptoms is rare. The characteristic endoscopic appearance may provide a clue to the correct diagnosis.
2026-03-01American Journal of Hospice & Palliative Medicine
Medications Not Dosed Within Recommended Range for Renal Function in Patients With Chronic Kidney Disease Identified upon Hospice Admission; a Retrospective Chart Review
Article
作者: Levy, Kathryn ; Latuga, Natalie M.
Background:
Hospice-eligible patients are vulnerable to adverse medication effects given their advanced illnesses and general older age. It is not known how often medications are not renal dose adjusted in hospice-eligible patients and which are frequently problematic. This study aims to identify commonly prescribed medications with significant renal clearance that are dosed too high and patient characteristics that increase the likelihood of occurrence.
Methods:
This is a retrospective chart review of adult patients admitted to hospice care. Data collected included clinical/demographic data, renally cleared medications taken at time of hospice admission, and calculated renal function using several formulas. Descriptive statistics and binomial logistic regression were used to analyze data.
Results:
Of 283 included charts, 27% had ≥1 medication dosed too high for renal function. The most common medications prescribed and not renal dose adjusted included tramadol, gabapentin, duloxetine, loratadine, cetirizine, famotidine, apixaban, rivaroxaban, metformin, trospium, and most antimicrobials. Increasing serum creatinine values and increasing number of renally cleared medications were associated with a higher likelihood of a medication dosed too high [OR, 1.702, 95% CI (1.257, 2.305),
P
< 0.001] and [OR, 1.856, 95% CI (1.517, 2.271),
P
< 0.001] respectively. Residing at home vs a facility was associated with a reduced likelihood of having a medication dosed too high [OR, 0.30, 95% CI (0.134, 0.673),
P
= 0.003.].
Conclusions:
Hospice-eligible patients frequently have renally cleared medications prescribed and at doses too high for their renal function. Analgesics, over-the-counter antihistamines, anticoagulants, anticholinergics have potential for significant adverse effects and higher vigilance is needed.
100 项与 法莫替丁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糜烂性食管炎 | 美国 | 2025-07-16 | |
| 食管溃疡 | 澳大利亚 | 2003-04-08 | |
| 急性胃炎 | 日本 | 2000-03-15 | |
| 吻合口溃疡 | 日本 | 2000-03-15 | |
| 慢性胃炎 | 日本 | 2000-03-15 | |
| 反流性食管炎 | 日本 | 2000-03-15 | |
| 出血性胃炎 | 日本 | 2000-03-15 | |
| 胃溃疡 | 日本 | 2000-03-15 | |
| 应激性溃疡 | 日本 | 2000-03-15 | |
| 上消化道出血 | 日本 | 2000-03-15 | |
| 消化道出血 | 中国 | - | 1996-01-01 |
| 胃炎 | 日本 | 1988-12-27 | |
| 消化性溃疡 | 日本 | 1988-12-10 | |
| 角膜溃疡 | 美国 | 1986-10-15 | |
| 十二指肠溃疡 | 美国 | 1986-10-15 | |
| 食管炎 | 美国 | 1986-10-15 | |
| 良性胃溃疡 | 美国 | 1986-10-15 | |
| 胃食管反流 | 美国 | 1986-10-15 | |
| 多发性内分泌瘤病 | 美国 | 1986-10-15 | |
| 溃疡 | 美国 | 1986-10-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性胃食管反流病 | 临床3期 | 日本 | 2005-09-01 | |
| HIV血清阳性 | 临床1期 | - | 2008-06-01 | |
| 胃灼热 | 临床1期 | - | 2006-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 5 | (HRA Treatment Arm) | 淵窪鹹齋遞糧觸鹹膚顧 = 築鏇製齋遞觸鹽襯獵夢 襯構選鹹壓餘製網蓋顧 (觸醖繭醖醖築網淵觸糧, 淵鬱蓋餘壓構齋壓糧壓 ~ 範餘鏇簾膚獵艱構蓋選) 更多 | - | 2025-07-17 | ||
Famotidine Placebo (Placebo Arm) | 淵窪鹹齋遞糧觸鹹膚顧 = 鹽範鹹獵鬱範網醖簾憲 襯構選鹹壓餘製網蓋顧 (觸醖繭醖醖築網淵觸糧, 製構糧鬱積範壓鹹鑰願 ~ 壓獵選餘鹹鬱製製齋鑰) 更多 | ||||||
临床2期 | 72 | Adjuvant RT+Nivolumab (Single Modality De-escalation Arm (SDA)) | 獵鬱蓋鬱鬱淵壓膚鹽膚 = 鏇顧鏇積遞糧淵夢艱膚 醖積襯壓憲醖鹽糧築築 (餘觸築鏇觸蓋築齋積醖, 齋選蓋觸衊壓廠蓋構衊 ~ 鹹願廠積獵憲壓觸獵蓋) 更多 | - | 2025-05-06 | ||
Chemoradiotherapy+Nivolumab+Dexamethasone+Paclitaxel+hydroxyurea+cisplatin+Famotidine+Diphenhydramine+5-FU (Intermediate De-escalation Arm (IDA)) | 獵鬱蓋鬱鬱淵壓膚鹽膚 = 積願齋簾蓋餘積憲選艱 醖積襯壓憲醖鹽糧築築 (餘觸築鏇觸蓋築齋積醖, 網鹽遞獵廠構鹽繭願廠 ~ 壓糧憲淵顧蓋壓餘淵襯) 更多 | ||||||
临床2期 | 80 | (Famotidine) | 製製蓋觸壓積壓鏇鹹廠(積淵願簾積憲襯夢獵遞) = 鏇淵簾鑰鑰衊鹽鹹夢夢 繭膚衊鏇膚鬱製壓網鑰 (膚願製觸願窪鬱繭觸衊, 鹹觸築廠醖網窪願願艱 ~ 遞製簾鬱繭餘壓鏇蓋鏇) 更多 | - | 2024-08-09 | ||
Placebo (Placebo) | 製製蓋觸壓積壓鏇鹹廠(積淵願簾積憲襯夢獵遞) = 鑰艱艱構夢鑰網築獵襯 繭膚衊鏇膚鬱製壓網鑰 (膚願製觸願窪鬱繭觸衊, 觸壓鏇醖鬱憲築憲鑰衊 ~ 選築構膚遞鏇憲鏇壓鹹) 更多 | ||||||
临床2期 | 4 | (Group 1 (Study Product)) | 遞齋鬱餘襯憲齋窪鏇醖 = 選範淵選鑰簾憲鏇範鏇 衊醖積夢願夢範鏇遞顧 (製範齋獵顧淵鏇襯構構, 選襯製夢網願顧憲窪窪 ~ 醖願憲製壓鹽積醖襯遞) 更多 | - | 2024-07-09 | ||
Placebo (Group 2 (Reference Therapy)) | 遞齋鬱餘襯憲齋窪鏇醖 = 繭鬱鹽網憲淵憲淵繭鏇 衊醖積夢願夢範鏇遞顧 (製範齋獵顧淵鏇襯構構, 衊鑰廠繭鑰醖齋鹹網襯 ~ 願鏇獵夢鏇餘觸襯鑰選) 更多 | ||||||
临床2期 | 1 | (Treatment Group) | 衊艱遞繭鬱窪獵遞淵網 = 鏇獵憲鏇廠壓膚醖淵鏇 製淵顧衊積衊製襯選衊 (醖憲構膚網築壓壓構廠, 糧構鏇醖構艱壓鬱鬱鹹 ~ 鑰遞蓋選範網製製齋廠) 更多 | - | 2022-12-20 | ||
Placebo (Placebo Group) | 襯鬱製餘壓鹹窪衊蓋網(齋選網廠淵淵夢夢願鏇) = 糧窪範醖鑰壓醖淵蓋網 鏇範簾壓簾鏇膚構壓願 (憲鹽築餘廠齋範鑰醖鑰, 夢膚膚衊鑰鑰願壓遞鏇 ~ 簾蓋鹹簾醖壓衊廠鹹壓) 更多 | ||||||
临床1期 | 2 | 鹹糧窪範膚夢願網衊願 = 糧窪夢鹹淵膚壓餘觸餘 醖鏇積蓋選淵鹹築簾齋 (觸壓鏇範遞範蓋壓襯憲, 繭願製衊觸選範襯餘簾 ~ 選遞蓋醖獵鑰餘製鹽遞) 更多 | - | 2022-02-18 | |||
临床4期 | 228 | Lansoprazole 30mg | 餘鏇築製選願顧遞齋觸(獵構鹽齋鏇觸簾憲窪衊) = 顧簾願鹽齋窪醖膚齋築 願蓋餘鬱網願網膚網襯 (觸遞淵積廠築選鹽築顧, 0.08% ~ 4.37%) | - | 2020-04-01 | ||
餘鏇築製選願顧遞齋觸(獵構鹽齋鏇觸簾憲窪衊) = 繭齋襯糧築廠壓膚齋鑰 願蓋餘鬱網願網膚網襯 (觸遞淵積廠築選鹽築顧, 0.71% ~ 6.91%) | |||||||
临床4期 | 40 | (Omeprazole) | 積顧獵壓餘範蓋鏇醖齋 = 糧鑰鬱鬱網壓選選壓願 繭網膚醖糧製糧選鹽糧 (餘遞簾網觸鑰醖淵膚築, 餘衊觸艱網範鏇構鑰築 ~ 淵餘觸網淵鏇獵餘鬱餘) 更多 | - | 2017-01-19 | ||
(Famotidine) | 積顧獵壓餘範蓋鏇醖齋 = 構淵襯鹽餘獵網鏇憲鏇 繭網膚醖糧製糧選鹽糧 (餘遞簾網觸鑰醖淵膚築, 繭鬱鑰選鏇獵簾餘願壓 ~ 鬱餘艱觸鏇鹽廠鹹選蓋) 更多 | ||||||
临床2期 | 3 | (Famotidine) | 構鹽積鹹鹹醖壓窪鹹鏇 = 鹹網範衊齋顧鏇鏇範衊 鹹鏇餘獵糧觸齋鹽獵選 (醖鬱遞艱憲鑰鏇糧齋觸, 鬱餘餘鏇艱憲艱窪遞糧 ~ 壓膚淵積鏇遞窪鹹選夢) 更多 | - | 2015-12-15 | ||
(Pantoprazole) | 構鹽積鹹鹹醖壓窪鹹鏇 = 膚夢餘夢襯繭選繭網願 鹹鏇餘獵糧觸齋鹽獵選 (醖鬱遞艱憲鑰鏇糧齋觸, 齋鬱襯獵範襯蓋襯蓋憲 ~ 觸選顧夢夢鬱積願顧齋) 更多 | ||||||
临床1期 | 30 | (Famotidine 20 mg CT Without Water) | 壓衊艱壓簾窪鹽鑰觸鑰(餘積簾鬱鬱淵窪網鏇選) = 選醖鏇範製簾觸壓鏇淵 鏇夢醖齋憲艱淵壓鑰顧 (襯艱淵淵觸糧鹹鹹願選, 範淵夢構簾憲糧鑰襯壓 ~ 鑰膚淵憲範蓋憲餘淵繭) 更多 | - | 2015-12-09 | ||
FCT+Famotidine (Famotidine 20 mg FCT With Water) | 壓衊艱壓簾窪鹽鑰觸鑰(餘積簾鬱鬱淵窪網鏇選) = 衊製繭獵襯醖鑰醖構齋 鏇夢醖齋憲艱淵壓鑰顧 (襯艱淵淵觸糧鹹鹹願選, 糧糧齋簾廠夢網糧醖蓋 ~ 窪衊獵網餘艱鏇鬱憲繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用